Minerva Neurosciences, Inc (NERV)
PHARMACEUTICAL PREPARATIONS
Minerva Neurosciences, Inc (NERV) is listed on Nasdaq, where it has traded since July 1, 2014.
- Listed On
- Nasdaq
- Listed Since
- July 1, 2014
- Employees
- 7
- Market Cap
- $110M
About Minerva Neurosciences, Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 57 institutions reported holding NERV, with 42.3 million shares worth $234.8 million in aggregate. The largest reported holder was Federated Hermes, with 4.7 million shares worth $25.9 million. Of the 5 largest holders listed below, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Federated Hermes | 4,670,426 | $26M | Reduced 8.66% |
| Janus Henderson (Jupiter Topco) | 4,386,027 | $24M | Added 2.14% |
| Vivo Capital | 4,322,747 | $24M | Unchanged |
| Balyasny Asset Management | 4,257,000 | $24M | Reduced 0.04% |
| Logos Global Management | 3,288,777 | $18M | Added 2.29% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is NERV?
Minerva Neurosciences, Inc (NERV) is listed on Nasdaq, where it has traded since July 1, 2014.
Who are the largest institutional holders of NERV?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of NERV were Federated Hermes, Janus Henderson (Jupiter Topco) and Vivo Capital.
How many institutions own NERV?
57 institutions reported a position in NERV for the quarter ended June 30, 2026, worth $234.8 million in total.
Did institutions buy or sell NERV last quarter?
Of the 5 largest reported holders, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for NERV.
Every reported institutional holder, plus insider and congressional trades in NERV, on SentiSense.